# Aveta Biomics

Source: https://onco.cc/companies/aveta-biomics/  
OnCo record `aveta-biomics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aveta Biomics is a United States-based biotechnology company running 2 late-stage cancer trials of APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma.

## Summary

Aveta Biomics, based in Bedford, the United States, is a biotechnology company. Aveta Biomics develops oral immunotherapies for cancer that apply principles of evolutionary biology to reprogram the tumour-immune ecosystem upstream of checkpoint pathways. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma. The largest, NCT06011109 (Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Aveta Biomics, Inc.
- Tags: ctgov-sponsor
- HQ: Bedford
- Type: biotech
- Website: https://avetabiomics.com

## Sources

- Official website: https://avetabiomics.com
- ClinicalTrials.gov: trials led by Aveta Biomics: https://clinicaltrials.gov/search?lead=Aveta%20Biomics%2C%20Inc.

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- trials: [Safety and Efficacy of APG-157 in Head and Neck Cancer](https://onco.cc/trials/nct05312710/), [Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab](https://onco.cc/trials/nct06011109/)

---
JSON: https://onco.cc/api/v1/entities/aveta-biomics.json